This morning, NRx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Abbreviated New Drug Application (ANDA) for its preservative-free ketamine product, which it has previously called KETAFREE1. KETAFREE is a generic product, hence the ANDA pathway, and is thus approved with the same label as Ketalar, the first ketamine product approved by FDA…

Source

Previous articleWeekly Psychedelic Policy Briefing: Oct. 27, 2026
Next articleJackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art